As a clinical report from a phase Ib study (NCT01656642), Sullivan et al. evaluated a triple combinatorial therapy of atezolizumab (anti-PD-L1 antibody), cobimetinib (MEK inhibitor), and vemurafenib (BRAF inhibitor) in patients with BRAFV600-mutated metastatic melanoma. The gene discussed is MAP2K7; the disease is metastatic melanoma.